VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age

Journal of Allergy and Clinical Immunology 2026

View at publisher
Authors: David Mark Fleischer, Douglas Mack, Julie Wang, Jeffrey G. Leflein, Michael David O'Sullivan, Anne-Sophie Chhim, Katharine J. Bee, Helen Wang, Hugh Sampson
DOI: 10.1016/j.jaci.2025.12.566
Cited by: 0

Fields of Study & Subjects

Food Allergy and Anaphylaxis Research Allergic Rhinitis and Sensitization Drug-Induced Adverse Reactions

Publication details

Journal / source
Journal of Allergy and Clinical Immunology
Volume
157
Issue
2
Pages
AB189–AB189
Publication date
1 February 2026
Language
EN